Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor

被引：0

作者：

G. N. Zyuz’kov

V. V. Zhdanov

E. V. Udut

L. A. Miroshnichenko

E. V. Simanina

T. Yu. Polyakova

L. A. Stavrova

V. V. Udut

M. Yu. Minakova

A. M. Dygai

机构：

[1] E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine,

[2] National Research Tomsk State University,undefined

来源：

Bulletin of Experimental Biology and Medicine | 2016年 / 162卷

关键词：

signal pathways; JAK; progenitor cells; regenerative medicine; fibroblast growth factor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We studied the involvement of individual JAK kinases in the realization of the growth potential of mesenchymal precursors under the effect of fibroblast growth factor. The important role of JAK2 and JAK3 in determining the initial level of mitotic activity of progenitor cells and participation of JAK1 in this process under conditions of cytokine stimulation of progenitor cells were demonstrated. Specific inhibitors of these kinases reduced the yield of fibroblast CFU and the rate of their division. Moreover, blockade of JAK1, JAK2, and JAK3 under the effect of fibroblast growth factor was accompanied by an increase in the intensity of progenitor cell differentiation.

引用

页码：240 / 243

页数：3

共 50 条

[41] Mutations of JAK2, JAK3 and GATA1 in acute megakaryoblastic leukemia of Down syndrome
Hama, Asahito
Yagasaki, Hiroshi
Takahashi, Yoshiyuki
Matsumoto, Kimikazu
Kiyoi, Hitoshi
Kojima, Seiji
BLOOD, 2008, 111 (04) : 2493 - 2494
[42] IMPLICATIONS OF RUXOLITINIB, JAK1/JAK2 INHIBITOR, ON THE GRAFT EFFECT AGAINST LEUKEMIA IN NK CELLS
Carmen, Mestre-Duran
Carla, Martin-Cortazar
Al-Fonso, Navarro-Zapata
David, Bueno
Laura, Clares-Villa
Alicia, Pernas
Karima, Al-akioui
Luisa, Sisinni
Blanca, Garcia-Solis
Victor, Galan
Nerea, Matamala
Adela, Escudero
Cristina, Ferreras
Antonio, Perez-Martinez
HAEMATOLOGICA, 2021, 106 (10) : 29 - 30
[43] MEDI 120-Development of novel and potent inhibitors of JAK2: Structure activity relationship studies for optimiziation of JAK2 potency while minimizing JAK3 activity
Reddy, Venkata J.
Mereddy, Venkatram R.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 895 - 895
[44] THE JAK1/JAK2 INHIBITOR, RUXOLITINIB SUBSTANTIALLY AFFECTS NK CELL BIOLOGY
Schoenberg, K.
Janna, R.
Cornez, I.
Brossart, P.
Wolf, D.
BONE MARROW TRANSPLANTATION, 2014, 49 : S74 - S75
[45] The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
Choy, E. H. S.
Miceli-Richard, C.
Gonzalez-Gay, M. A.
Sinigaglia, L.
Schlichting, D. E.
Meszaros, G.
de la Torre, I.
Schulze-Koops, H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 694 - 704
[46] A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses
Kohlhuber, F
Rogers, NC
Watling, D
Feng, J
Guschin, D
Briscoe, J
Witthuhn, BA
Kotenko, SV
Pestka, S
Stark, GR
Ihle, JN
Kerr, IM
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (02) : 695 - 706
[47] JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
Wu, Junchao
Li, Lisha
Zhu, Quangang
Zhang, Tingrui
Miao, Fengze
Cui, Zhen
Dong, Guoqiang
Tai, Zongguang
Chen, Zhongjian
BIOMEDICINE & PHARMACOTHERAPY, 2024, 171
[48] Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
Mesa, Ruben A.
IDRUGS, 2010, 13 (06) : 394 - 403
[49] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A.
Laborde, R. R.
Lasho, T. L.
Finke, C.
Begna, K.
Al-Kali, A.
Hogan, W. J.
Litzow, M. R.
Leontovich, A.
Kowalski, M.
Tefferi, A.
LEUKEMIA, 2013, 27 (06) : 1322 - 1327
[50] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani
R R Laborde
T L Lasho
C Finke
K Begna
A Al-Kali
W J Hogan
M R Litzow
A Leontovich
M Kowalski
A Tefferi
Leukemia, 2013, 27 : 1322 - 1327

← 1 2 3 4 5 →